eGenesis
PrivateLast Round
Series D
Sep 4, 2024
Total Funding Raised
$454M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
eGenesis is a biotechnology company that specializes in gene editing and genome engineering to revolutionize solid organ and therapeutic cell transplantation for life-threatening diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
eGenesis Comparables
Compare eGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| United Therapeutics | 81% | |
| Makana Therapeutics | 79% | |
| NZeno | 79% |
eGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 4, 2024 | ||||
| Series C | Mar 2, 2021 | ||||
| Series B | Nov 7, 2019 | ||||
| Series A | Mar 16, 2017 |
Key People
Founding team and executive leadership
eGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SymBiosis Capital Management | Series C |
| Farallon Capital Management | Series D, Series C |
| LifeSci Venture Partners | Series C |
| Khosla Ventures | Series D, Series B, Series A, Series C |
| Parkwood | Series D |
| ARCH Venture Partners | Series D, Series B, Series C, Series A |
| Eisai Innovation | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Lead program EGEN-2784 in multi-patient Expanded Access study.
- Apr 18, 2026
Conducting clinical study for EGEN-2784 at Massachusetts General Hospital.
Recent news
Latest coverage and updates
- is_developingSep 28, 2026
Egenesis Inc. is developing programmes involving kidney transplantation, acute liver failure and heart transplantation on Sep 29th '26.
- launchesAug 25, 2026
Egenesis Inc. launched porcine kidney transplant in a living patient on Mar 1st '24.
eGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about eGenesis's valuation, stock price, and market status.
Is eGenesis a public or private company?
eGenesis is a private company.
What is the current stock price of eGenesis?
eGenesis is a private company with no public stock price. No recent secondary market data is available.
How much is eGenesis worth (valuation)?
Valuation information for eGenesis is not publicly available.
Can I buy eGenesis stock?
eGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was eGenesis's last funding round?
eGenesis's most recent funding round was Series D on September 4, 2024.
Who are the main investors in eGenesis?
Key investors in eGenesis include Osage University Partners, Lux Capital, Catalio Capital Management, Biomatics Capital Partners, Irving Investors.
Will eGenesis IPO soon?
No public IPO plans have been announced for eGenesis.
How can I track eGenesis secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor eGenesis's secondary market activity and sign up for updates.